GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (NAS:IGMS) » Definitions » Beneish M-Score

IGM Biosciences (IGM Biosciences) Beneish M-Score : -2.15 (As of May. 03, 2024)


View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.15 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for IGM Biosciences's Beneish M-Score or its related term are showing as below:

IGMS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.15   Med: -2.15   Max: -2.15
Current: -2.15

During the past 7 years, the highest Beneish M-Score of IGM Biosciences was -2.15. The lowest was -2.15. And the median was -2.15.


IGM Biosciences Beneish M-Score Historical Data

The historical data trend for IGM Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Beneish M-Score Chart

IGM Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - - - -2.15

IGM Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.77 -1.54 -2.15

Competitive Comparison of IGM Biosciences's Beneish M-Score

For the Biotechnology subindustry, IGM Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGM Biosciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGM Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where IGM Biosciences's Beneish M-Score falls into.



IGM Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of IGM Biosciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 1.0951+0.892 * 1.9925+0.115 * 0.763
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5053+4.679 * -0.127925-0.327 * 1.169
=-2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0.651 + 0.509 + 0.448 + 0.522 = $2.13 Mil.
Gross Profit was 0.651 + 0.509 + 0.448 + 0.522 = $2.13 Mil.
Total Current Assets was $347.60 Mil.
Total Assets was $423.41 Mil.
Property, Plant and Equipment(Net PPE) was $74.01 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.28 Mil.
Selling, General, & Admin. Expense(SGA) was $50.07 Mil.
Total Current Liabilities was $42.48 Mil.
Long-Term Debt & Capital Lease Obligation was $34.67 Mil.
Net Income was -60.695 + -61.989 + -64.423 + -59.309 = $-246.42 Mil.
Non Operating Income was 0 + 0 + 0 + -0.02 = $-0.02 Mil.
Cash Flow from Operations was -48.008 + -40.121 + -53.105 + -50.997 = $-192.23 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.372 + 0.331 + 0.366 + 0 = $1.07 Mil.
Gross Profit was 0.372 + 0.331 + 0.366 + 0 = $1.07 Mil.
Total Current Assets was $438.42 Mil.
Total Assets was $513.50 Mil.
Property, Plant and Equipment(Net PPE) was $73.08 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.08 Mil.
Selling, General, & Admin. Expense(SGA) was $49.74 Mil.
Total Current Liabilities was $44.69 Mil.
Long-Term Debt & Capital Lease Obligation was $35.36 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 2.13) / (0 / 1.069)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.069 / 1.069) / (2.13 / 2.13)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (347.597 + 74.005) / 423.411) / (1 - (438.421 + 73.075) / 513.499)
=0.004272 / 0.003901
=1.0951

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.13 / 1.069
=1.9925

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.075 / (6.075 + 73.075)) / (8.277 / (8.277 + 74.005))
=0.076753 / 0.100593
=0.763

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(50.072 / 2.13) / (49.736 / 1.069)
=23.507981 / 46.525725
=0.5053

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((34.672 + 42.481) / 423.411) / ((35.356 + 44.685) / 513.499)
=0.182218 / 0.155874
=1.169

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-246.416 - -0.02 - -192.231) / 423.411
=-0.127925

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

IGM Biosciences has a M-score of -2.15 suggests that the company is unlikely to be a manipulator.


IGM Biosciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


IGM Biosciences (IGM Biosciences) Business Description

Traded in Other Exchanges
Address
325 East Middlefield Road, Mountain View, CA, USA, 94043
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Executives
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Fred Schwarzer director, officer: CEO and President 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Bruce Keyt officer: Chief Scientific Officer 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Lisa Lynn Decker officer: Chief Business Officer C/O ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
George Gauthier officer: Chief Commercial Officer C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Chris H Takimoto officer: Chief Medical Officer C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Misbah Tahir officer: Chief Financial Officer 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Thompson Elizabeth H.z. director C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Christina Teng Topsoe director, 10 percent owner 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Jakob Haldor Topsoe director, 10 percent owner 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Michael D Loberg director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Steven Weber officer: Principal Accounting Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014